Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives.
Future Oncol
; 7(4): 551-8, 2011 Apr.
Article
em En
| MEDLINE
| ID: mdl-21463143
ABSTRACT
Prostate cancer represents a third of all newly diagnosed cancers in men in the USA with an estimated incidence of 192,280 cases and 27,360 deaths in 2009. It continues to be a major cause of cancer-related morbidity and mortality, and there is an urgent need for new treatments. Historically, systemic therapy options were limited after progression on docetaxel-based chemotherapy. This article reviews current data on the novel therapeutics demonstrating activity in metastatic castration-resistant prostate cancer and their future role in the treatment of this disease with a poor prognosis.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Descoberta de Drogas
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Humans
/
Male
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Estados Unidos